• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Inactivated whole-virion SARS-CoV-2 vaccine reduces rates of symptomatic COVID-19 infections

byNeel MistryandTeddy Guo
July 27, 2021
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Incidence of PCR-confirmed symptomatic COVID-19 cases was lower in the vaccine group compared with the placebo group (p<0.0001).

2. The majority of adverse events were mild and there was no vaccine-related mortality. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: Inactivated vaccines offer a variety of benefits against transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One such inactivated whole-virion vaccine is CoronaVac, which is currently in phase 3 trials in Brazil, Indonesia, Chile, and Turkey. This phase III randomized controlled trial aimed to assess the safety and efficacy of CoronaVac in Turkey. Primary outcome for this study was the proportion of laboratory confirmed COVID-19 cases at least 14 days after administering the second dose, while key secondary outcomes included incidence of hospitalization, adverse events, and mortality. According to study results, the vaccine group reported significantly fewer cases of symptomatic COVID-19 compared with placebo; however, the frequency of adverse events was higher in the former. In addition, no individuals in the vaccine group required hospitalization for their infection. While this study was well done, a major limitation was that it did not explore the impact of vaccine interchangeability on the aforementioned clinical outcomes. Nevertheless, it provides valuable insight into the use of CoronaVac for safe and effective immunogenicity during the COVID-19 pandemic.

Click to read the study in The Lancet

Relevant Reading: Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

In-depth [randomized controlled trial]: Between Sept 14, 2020, and Jan 5, 2021, 11 303 patients were assessed for eligibility across 24 centers in Turkey. Included patients were between 18-59 years of age with no previous history of COVID-19 and a negative SARS-CoV-2 PCR or antibody test. Those diagnosed with a bleeding disorder or on immunosuppressants were excluded. Altogether, 10 214 patients in the intention-to-treat group (65.1% in vaccine group vs. 34.9% in placebo group) and 10 029 patients in the per-protocol group (65.4% in vaccine group vs. 34.6% in placebo group) completed the trial. Median age among enrolled patients was 45 years (interquartile range [IQR] 37-51) and the majority (57.8%) were male.

RELATED REPORTS

Unvaccinated status increases risk of long COVID symptoms

Meta-analysis details short-term outcomes of SARS-CoV-2 mRNA vaccine-associated myopericarditis in adolescents and young adults

Evolving standard of care guidelines have improved outcomes in hospitalized COVID-19 patients

The primary outcome of PCR-confirmed COVID-19 cases two weeks after receiving the second dose was lower in the vaccine group (31.7 cases per 1000 person-years, IQR 14.6-59.3) compared with the placebo group (192.3 cases per 1000 person-years, IQR 135.7-261.1; p<0.0001). This was also true with regard to the number of hospitalizations. More patients in the placebo group (36.4 hospitalizations per 1000 person-years, IQR 13.5-77.5) were admitted due to COVID-19 than in the vaccine group (0 hospitalizations per 1000 person-years), giving a 100% vaccine efficacy (95% confidence interval [CI] 20.4-100.0, p=0.0344). However, the incidence of serious adverse events was greater among patients in the vaccine group (n=1259, 18.9%) than in the placebo group (n=603, 16.9%, p=0.0108), with the most common systemic adverse event being fatigue (8.2% in vaccine group vs. 7.0% in placebo group, p=0.0228). There were no serious adverse events or mortality. Findings from this study suggest a high safety and efficacy profile for CoronaVac against symptomatic SARS-CoV-2 infection. 

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: coronarvirusCoronaVaccovidcovid vaccinecovid-19 infectionCOVID-19 Vaccineinactivated whole-virion vaccineSARS-CoV-2
Previous Post

Delayed endovascular thrombectomy associated with greater clinical benefit among patients with mismatch imaging profiles in treatment of subacute ischemic stroke

Next Post

Suicide incidence and risk among patients with head and neck cancer in rural vs urban areas

RelatedReports

Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Unvaccinated status increases risk of long COVID symptoms

January 25, 2023
Compliance-linked incentives increase infant immunizations rates in rural India
Cardiology

Meta-analysis details short-term outcomes of SARS-CoV-2 mRNA vaccine-associated myopericarditis in adolescents and young adults

January 3, 2023
Palliative chemotherapy associated with more ICU treatment at end-of-life
Infectious Disease

Evolving standard of care guidelines have improved outcomes in hospitalized COVID-19 patients

December 23, 2022
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Cardiology

Slight increase of incidence of myocarditis post-mRNA SARS-CoV-2 vaccination

December 15, 2022
Next Post
Cancer to surpass heart disease as leading cause of death in the U.S. for higher-income persons

Suicide incidence and risk among patients with head and neck cancer in rural vs urban areas

Being overweight and obese associated with increased incidence of chronic kidney disease

Impact of point-of-care screening for hypertension, diabetes, and progression of chronic kidney disease in rural Manitoba Indigenous communities

Study identifies distinct hemoglobin A1c patterns in adolescents over time

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options